Back to results
US 2014/0275137 A1Published application
Tetrandrine family pharmaceutical formulations and method
AssigneeCBA Pharma, Inc.
InventorRon D. Carroll
Life of this patent
Estimating the term…
Abstract
Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.
Claims20
A pharmaceutical formulation comprising:
- the pure di-acid salt of a tetrandrine family member having the following formula:
- where R1 and R1′ are the same or different short chained carbon based ligand including without limitation, CH3, CO2CH3 or H;
- and R2 is CH3 or C2H5;
- and R3 is CH3 or hydrogen;
- and a pharmaceutical carrier.
2 more elements
A method of forming the di-acid salt of a tetrandrine family member having the following formula:
- where R1 and R1′ are the same or different short chained carbon based ligand including without limitation, CH3, CO2CH3 or H;
- and R2 is CH3 or C2H5;
- and R3 is CH3 or hydrogen, said method comprising:
- dissolving a purified member of the tetrandrine family in a 2 molar equivalent dilute acid solution, feeding said solution through a spray drier set with a wall temperature of 240-400 C, and an atomizer set to feed the di-acid salt solution at a rate of 1-2 liters/minute.
1 more element
The pure di-acid salt of a tetrandrine family member having the following formula:
- where R1 and R1′ are the same or different short chained carbon based ligand including without limitation, CH3, CO2CH3 or H;
- and R2 is CH3 or C2H5;
- and R3 is CH3 or hydrogen.
The di-acid salt of a tetrandrine family member having the following formula:
- where R1 and R1′ are the same or different short chained carbon based ligand including without limitation, CH3, CO2CH3 or H;
- and R2 is CH3 or C2H5;
- and R3 is CH3 or hydrogen, which is made by the process of claim 26.
Dependencies are inferred from the claim text.